Nicotine, brain nicotinic receptors, and neuropsychiatric disorders

Archives of Medical Research

Volumn 31, Issue 2, 2000, Pages 131-144

  Mihailescu, Stefan ^a   Drucker Colín, René ^b  

^a Fac Med And Inst Fisiol C ^*  (Mexico)

^b INSTITUTO DE FISIOLOGÍA CELULAR   (Mexico)

Author keywords

Alzheimer's disease; Attention deficit hyperactivity disorder; Depression; Nicotine; Nicotinic acetylcholine receptors; Parkinson's disease; Schizophrenia; Tourette's syndrome

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; CATION CHANNEL; MECAMYLAMINE; N METHYL 4 (3 PYRIDINYL) 3 BUTENAMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR;

ADDICTION; ALZHEIMER DISEASE; ATTENTION; ATTENTION DEFICIT DISORDER; BEHAVIOR; BRAIN; COGNITION; DEPRESSION; DRUG MECHANISM; FRONTAL LOBE EPILEPSY; GILLES DE LA TOURETTE SYNDROME; HUMAN; MEMORY; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROPSYCHIATRY; NONHUMAN; PARKINSON DISEASE; REVIEW; SCHIZOPHRENIA;

ADULT; ALZHEIMER DISEASE; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; DEPRESSION; DOPAMINE; DRUG INTERACTIONS; EPILEPSIES, PARTIAL; HUMANS; ION CHANNEL GATING; MENTAL DISORDERS; NEUROTRANSMITTER AGENTS; NICOTINE; PARKINSON DISEASE; RATS; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; SELF MEDICATION; SMOKING; TOBACCO USE DISORDER; TOURETTE SYNDROME;

EID: 0034603508     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0188-4409(99)00087-9     Document Type: Review

References (222)

1. Watson M., Roeske W.R., Yamura I.H. The third generation of progress. Meltzer H. Psychopharmacology. 1987;Raven Press, New York. 241.p.
2. Changeux J., Galzi A., Devillers-Thiery A., Bertrand D. The functional architecture of the acetylcholine nicotine receptor explored by affinity labeling and site directed mutagenesis. Rev Biophys. 25:1992;395.
3. Changeux J.P., Bertrand D., Corringer P.J., Dehaene S., Edelstein S., Lena C., Le Novere N., Marubio L., Picciotto M., Zoli M. Brain nicotinic receptors. structure and regulation, role in learning and reinforcement Brain Res Rev. 26:1998;198.
4. Sargent P.B. The diversity of neuronal nicotinic acetylcholine receptors. Annu Rev Neurosci. 16:1993;403.
5. Anand R., Lindstrom J. Nucleotide sequence of the human nicotinic acetylcholine receptor in α2 subunit gene. Nucleic Acids Res. 18:1990;4272.
6. Chini B., Clementi F., Hukovic N., Sher E. Neuronal type α-bungarotoxin receptors and the α5 nicotinic receptor subunit gene are expressed in neuronal and non-neuronal human cell lines. Proc Natl Acad Sci USA. 89:1992;1572.
7. Doucette-Stamm L., Monteggia L.M., Donnelly-Roberts D., Wang M.T., Lee J., Tian J., Giordano T. Cloning and sequence of the human α7 nicotinic acetylcholine receptor. Drug Dev Res. 30:1993;252.
8. Elliott K.J., Ellis S.B., Berckhan K.J., Urrutia A., Chavez-Noriega L.E., Johnson E.C., Velicelebi G., Harpold M.M. Comparative structure of human neuronal alpha 2-alpha 7 and beta 2-beta 4 nicotinic acetylcholine receptor subunits and functional expression of the alpha 2, alpha 3, alpha 4, alpha 7, beta 2, and beta 4 subunits. J Mol Neurosci. 7:1996;217.
9. McGehee D.S., Role W. Physiological diversity of nicotinic acetylcholine receptors. Annu Rev Physiol. 57:1995;521.
10. Gerzanich V., Wang F., Kuryatov A., Lindstrom J. alpha 5 Subunit alters desensitization, pharmacology, Ca++ permeability and Ca++ modulation of human neuronal alpha 3 nicotinic receptors. J Pharmacol Exp Ther. 286:1998;311.
11. Le Novère N., Zoli M., Changeux J.P. Neuronal nicotinic receptor alpha 6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur J Neurosci. 8:1996;2428.
12. Whiting P., Lindstrom J. Pharmacological properties of immuno-isolated neuronal acetylcholine receptors. J Neurosci. 6:1986;3061.
13. Conroy W.G., Berg D.K. Neurons can maintain multiple classes of nicotinic acetylcholine receptors distinguished by different subunit compositions. J Biol Chem. 270:1995;4424.
14. Seguela P., Wadiche J., Dineley-Miller K., Dani J.A., Patrick J.W. Molecular cloning, functional properties and distribution of rat brain α7. a nicotinic cation channel highly permeable to calcium J Neurosci. 13:1993;596.
15. Gotti C., Hanke W., Moretti M., Ballivet M., Clementi F., Bertrand D. Pharmacology and biophysical properties of α7 and α7-8 h α-bungarotoxin receptor subtypes immunopurified from the chick optic lobe. Eur J Neurosci. 6:1994;1281.
16. Gotti M., Moretti M., Maggi R., Longhi R., Hanke W., Klinke N.et al. α7 and α8 Nicotinic receptor subtypes immunopurified from chick retina have different immunological, pharmacological and functional properties. Eur J Neurosci. 5:1997;1201.
17. Luetje C.W., Patrick J. Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J Neurosci. 11:1991;837.
18. Chavez-Noriega L.E., Crona J.H., Washburn M.S., Urrutia A., Elliott K.J., Johnson E.C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J Pharmacol Exp Ther. 280:1997;346.
19. Stauderman K.A., Mahaffy L.S., Akong M., Velicelebi G., Chavez-Noriega L.E., Crona J.H., Johnson E.C., Elliott K.J., Gillespie A., Reid R.T., Adams P., Harpold M.M., Corey-Naeve J. Characterization of human recombinant neuronal nicotinic acetylcholine receptor subunit combinations alpha2beta4, alpha3beta4 and alpha4beta4 stably expressed in HEK293 cells. J Pharmacol Exp Ther. 284:1998;777.
20. Harvey S.C., McIntosh J.M., Cartier G.E., Maddox F.N., Luetje C.W. Determinants of specificity for alpha-conotoxin MII on alpha3beta2 neuronal nicotinic receptors. Mol Pharmacol. 51:1997;336.
21. Papke R.L. The kinetic properties of neuronal nicotinic acetylcholine α3-receptors. Prog Neurobiol. 41:1993;509.
22. Papke R.L., Heinemann S.F. The role of β4 subunits in determining the kinetic properties of rat neuronal nicotinic acetylcholine α3-receptors. J Physiol. 440:1991;95.
23. Papke R.L., Heinemann S.F. Partial agonist properites of cytisine on neuronal acetylcholine α3-receptors. Mol Pharmacol. 45:1993;142.
24. Role L.W., Berg D.K. Nicotinic receptors in the development and modulation of CNS synapses. Neuron. 16:1996;1077.
25. Gotti C., Fornasari D., Clementi F. Human neuronal nicotinic receptors. Prog Neurobiol. 53:1997;199.
26. Decker M.W., Brioni J.D., Bannon A.W., Arneric S.P. Diversity of neuronal nicotinic acetylcholine receptors. lessons from behavior and implications for CNS therapeutics Life Sci. 56:1995;545.
27. Sacaan A.I., Reid R.T., Santori E.M., Adams P., Correa L.D., Mahaffy L.S., Bleicher L., Cosford N.D., Stauderman K.A., McDonald I.A., Rao T.S., Lloyd G.K. Pharmacological characterization of SIB-1765F. a novel cholinergic ion channel agonist J Pharmacol Exp Ther. 280:1997;373.
28. Lloyd G.K., Menzaghi F., Bontempi B., Suto C., Siegel R., Akong M., Stauderman K., Velicelebi G., Johnson E., Harpold M.M., Rao T.S., Sacaan A.I., Chavez-Noriega L.E., Washburn M.S., Vernier J.M., Cosford N.D.P., McDonald L.A. The potential of subtype-selective neuronal acetylcholine receptor agonists as therapeutic agents. Life Sci. 62:1998;1601.
29. Couturier S., Bertrand D., Matter J.M., Hernandez M.C., Bertrand S., Millar N., Valera S., Barkas T., Ballivet M. A neuronal nicotinic acetylcholine receptor subunit (alpha7) is developmentally regulated and forms a homooligomeric channel blocked by α-BTX. Neuron. 5:1990;847.
30. Mulle C., Léna C., Changeux J.P. Potentiation of nicotinic receptor response by external calcium in central neurons. Neuron. 8:1992;937.
31. Vernino S., Amador M., Luetje C.W., Patrick J., Dani J.A. Calcium modulation and high calcium permeability of neuronal nicotinic acetylcholine receptors. Neuron. 8:1992;127.
32. Pereira E.F., Alkondon M., Reinhardt S., Maelicke A., Peng X., Lindstrom J., Whiting P., Albuquerque E.X. Physostigmine and galanthamine. probes for a novel binding site on the alfa 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stable expressed in fibroblast cells J Pharmacol Exp Ther. 270:1994;768.
33. Garcia-Colunga J., Miledi R. Effects of serotonergic agents on neuronal nicotinic acetylcholine receptors. Proc Natl Acad Sci USA. 92:1995;2919.
34. Cross K.M.L., Foreman R.C., Chad J.E. Enhancement by 5-hydroxytryptamine and analogues of desensitization of neuronal and muscle nicotinic receptors expressed in Xenopus oocytes. Br J Pharmacol. 114:1995;1636.
35. Albuquerque E.X., Pereira E.F.R., Alkondon M., Schrattenholtz A., Maelicke A. Nicotinic acetylcholine receptor on hippocampal neurons. distribution on the neuronal surface and modulation of receptor activity J Res Rec. 17:1997;243.
36. Schmid H.A., Vijayaraghavan S. Inhibition of the nicotinic acetylcholine receptor response by serotoninergic and muscarinic agents in ciliary ganglion neurones. Neuropsychopharmacology. 31:1992;1001.
37. Marszalec W., Aistrup G.L., Narahashi T. Ethanol-nicotine interactions at alpha-bungarotoxin-insensitive nicotinic acetylcholine receptors in rat cortical neurons. Alcohol Clin Exp Res. 23:1999;439.
38. Ke L., Lukas R.J. Effects of steroid exposure on ligand binding and functional activities of diverse nicotinic acetylcholine receptors subtypes. J Neurochem. 67:1996;1100.
39. Gandia L., Villaroya M., Sala F., Reig J.-A., Viniegra S., Quintanar J.-L.et al. Inhibition of nicotinic receptor-mediated responses in bovine chromaffin cells by diltiazem. Br J Pharmacol. 118:1996;1301.
40. Badio B., Padgett W.L., Daly J.W. Ibogaine. a potent, non-competitive blocker of ganglionic/neuronal nicotinic receptors Mol Pharmacol. 51:1997;1.
41. Fryer J.D., Lukas R.J. Noncompetitive functional inhibition at diverse human nicotinic receptor subtypes by bupropion, phencyclidine and ibogaine. J Pharmacol Exp Ther. 288:1999;88.
42. Role L.W. Substance P modulation of acetylcholine-induced currents in embryonic chicken sympathetic and ciliary ganglion neurons. Proc Natl Acad Sci USA. 81:1984;2924.
43. Simmons L.K., Schuetze S.M., Role L.W. Substance P modulates single-channel properties of neuronal nicotinic acetylcholine receptors. Neuron. 4:1990;393.
44. Valenta D.C., Downing J.E., Role L.W. Peptide modulation of ACh receptor desensitization controls neurotransmitter release from chicken sympathetic neurons. J Neurophysiol. 69:1993;928.
45. Clarke P.B.S. Nicotinic receptors in mammalian brain. localization and relation to cholinergic function Prog Brain Res. 98:1993;77.
46. Nicoll R.A., Malenka R.C., Kauer J.A. Functional comparison of neurotransmitter subtypes in the mammalian central nervous system. Physiol Rev. 70:1990;513.
47. Garza R., McGuire T.J., Freedman R., Hoffer B.J. The electrophysiological effects of nicotine in the rat cerebellum. evidence for direct postsynaptic actions Neurosci Lett. 80:1987;303.
48. Léna C., Changeux J.P., Mulle C. Evidence of "preterminal" nicotinic receptors on GABAergic axons in the rat interpeduncular nucleus. J Neurosci. 13:1993;2680.
49. Wonnacott S. Presynaptic nicotinic ACh receptors. TINS. 20:1997;92.
50. 3H]dopamine release from rat striatal synaptosomes. Neuropharmacology. 34:1995;1535.
51. 3H]-dopamine release Br J Pharmacol. 117:1996;595.
52. Sacaan A.I., Dunlop J.L., Lloyd G.K.J. Pharmacological characterization of neuronal acetylcholine gated ion channel receptor-mediated hippocampal norepinephrine and striatal dopamine release from rat brain slices. Pharmacol Exp Ther. 274:1995;224.
53. Whiteaker P. Locomotor activation and dopamine release produced by nicotine and isoarecolone in rats. Br J Pharmacol. 116:1995;2097.
54. 3H] methylcarbamylcholine binding sites and effect of N-methylcarbamylcholine on acetylcholine release in rat brain. J Neurochem. 51:1988;292.
55. McGehee D.S., Heath M.J., Devay P., Role L.W. Nicotine enhancement of fast synaptic transmission in CNS by presynaptic receptors. Science. 269:1995;1692.
56. Gotti C., Briscini L., Verderio C., Oortgiesen M., Balestra B., Clementi F. Native nicotinic acetylcholine receptors in human IMR32 neuroblastoma cells. functional, immunological and pharmacological properties Eur J Neurosci. 7:1995;2083.
57. 3H]dopamine release from rat striatal synaptosomes. J Neurochem. 67:1996;163.
58. Pugh P.C., Berg D.K. Neural nicotine acetylcholine receptors that bind α-bungarotoxin mediate neurite retraction in a calcium-dependent manner. J Neurosci. 14:1994;889.
59. Greenberg M.E., Ziff E.B., Greene L.A. Stimulation of neuronal acetylcholine receptors induces rapid gene transmission. Science. 234:1986;80.
60. 2+ signaling pathways converge on CaM kinase in PC12 cells. FEBS Lett. 304:1992;237.
61. Vijayaraghavan S., Huang B., Blumenthal E.M., Berg D.K. Arachidonic acid as a possible negative feed back inhibitor of nicotinic acetylcholine receptors on neurons. J Neurosci. 15:1995;3679.
62. Marks M.J., Burch J.B., Collins A.C. Effects of chronic nicotine infusion on tolerance development and cholinergic receptors. J Pharmacol Exp Ther. 259:1983;392.
63. Schwartz R.D., Kellar K.J. Nicotinic cholinergic receptor binding sites in the brain. regulation in vivo Science. 220:1983;214.
64. 3H]nicotine binding sites in human brain. J Neurochem. 50:1988;1243.
65. 3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther. 282:1997;7.
66. Peng X., Gerzanich V., Anand R., Whiting P.J., Lindstrom J. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol Pharmacol. 46:1994;523.
67. Zhang X., Gong Z.-H., Hellstrom-Kindahl E., Norberg A. Regulation of α4β2 nicotinic acetylcholine receptor in M10 cells following treatment with nicotinic agents. Neuroreport. 6:1994;313.
68. Bencheriff M., Fowler K., Lukas R.J., Lipiello P.M. Mechanisms of up-regulation of neuronal nicotinic acetylcholine receptor in clonal cell lines and primary cultures of fetal rat brain. J Pharmacol Ther. 275:1995;987.
69. Lohse M.J. Molecular mechanisms of membrane receptor desensitization. Biochim Biophys Acta. 1179:1993;171.
70. Sanderson E.M., Drasdo A.L., McCrea K., Wonnacott S. Up-regulation of nicotinic receptors following continual infusion of nicotine is brain-region-specific. Brain Res. 617:1993;349.
71. Collins A.C., Marks M.J. Are nicotinic receptors activated or inhibited following chronic nicotine treatment? Drug Dev Res. 38:1996;231.
72. Molinari E.J., Delbono O., Messi M.L., Rengathan M., Arneric S.P., Sullivan J.P., Gopalakrishnan M. Up-regulation of human α7 nicotinic receptors by chronic treatment with activator and antagonist ligands. Eur J Pharmacol. 347:1998;131.
73. Whiteaker P., Sharples C.V.G., Wonnacott S. Agonist-induced up-regulation of α4β2 nicotinic acetylcholine receptor in M10. pharmacological and spatial definition Mol Pharmacol. 53:1998;950.
74. Marks M.J., Pauly J.R., Gross S.D., Deneris E.S., Hermans-Borgemeyer I., Heinemann S., Collins A.C. Nicotine binding and nicotinic receptor subunit mRNA after chronic nicotinic treatment. J Neurosci. 12:1992;2765.
75. Lukas R.J., Ke L., Bencheriff M., Eisenhour C.M. Regulation by nicotine of its own receptors. Drug Dev Res. 38:1996;136.
76. 3H]-acetylcholine to nicotinic receptors. Psychopharmacology. 24:1985;527.
77. 3H]-nicotine binding sites Synapse. 21:1995;281.
78. Janson A.M., Fuxe K., Agnati L.F., Jansson A., Bjelke B., Sundstrom E., Andersson K., Harfstrand A., Goldstein M., Owman C. Protective effects of chronic nicotine treatment on lesioned nigrostriatal dopamine neurons in the male rat. Prog Brain Res. 79:1989;257.
79. Fuxe K., Janson A.M., Jansson A., Andersson K., Eneroth P., Agnati L.F. Chronic nicotine treatment increases dopamine levels and reduces dopamine utilization in substantia nigra and in surviving forebrain dopamine nerve terminal systems after a partial di-mesencephalic hemitransection. Naunyn Schmiedebergs Arch Pharmacol. 341:1990;171.
80. Kihara T., Shimohama S., Sawada H., Kimura J., Kume T., Kochiyama H., Maeda T., Akaike A. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol. 42:1997;159.
81. Nanri M., Yamamoto J., Miyake H., Watanabe H. Protective effect of GTS-21, a novel nicotinic receptor agonist, on delayed neuronal death induced by ischemia in gerbils. Jpn J Pharmacol. 76:1998;23.
82. Nanri M., Watanabe H. Availability of 2VO rats as a model for chronic cerebrovascular disease. Nippon Yakurigaku Zasshi. 113:1999;85.
83. Nanri M., Kasahara N., Yamamoto J., Miyake H., Watanabe H. GTS-21, a nicotinic agonist, protects against neocortical neuronal cell loss induced by the nucleus basalis magnocellularis lesion in rats. Jpn J Pharmacol. 74:1997;285.
84. Meyer E.M., King M.A., Meyers C. Neuroprotective effects of 2,4-dimethoxybenzylidene anabaseine (DMXB) and tetrahydroaminoacridine (THA) in neocortices of nucleus basalis lesioned rats. Brain Res. 786:1998;252.
85. Shimohama S., Greenwald D.L., Shafron D.H., Akaika A., Maeda T., Kaneko S., Kimura J., Simpkins C.E., Day A.L., Meyer E.M. Nicotinic alpha 7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res. 779:1998;359.
86. Li Y., Papke R.L., He Y.J., Millard W.J., Meyer E.M. Characterization of the neuroprotective and toxic effects of alpha7 nicotinic receptor activation in PC12 cells. Brain Res. 830:1999;218.
87. Donnelly-Roberts D.L., Xue I.C., Arneric S.P., Sullivan J.P. In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418. Brain Res. 719:1996;36.
88. Stolerman I.P., Shoaib M. The neurobiology of tobacco addiction. TIPS. 12:1991;467.
89. Dani J.A., Heinemann S. Molecular aspects of nicotine abuse. Neuron. 16:1996;905.
90. Kalivas P.W., Stewart J. Dopamine transmission in the initiation of and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev. 16:1991;223.
91. Corrigal W.A., Coen K.M. Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology. 104:1991;171.
92. Corrigal W.A., Coen K.M., Adamson K. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res. 653:1994;278.
93. Pontieri F.E., Tanda G., Orzi F., Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature. 382:1996;255.
94. Jaffe J.H. Drug addiction and drug abuse. Goodman G., Rall T.W., Nies A.S., Taylor P. Goodman's and Gilman's The pharmacological basis of therapeutics. 1990;Pergamon Press, New York. 548.p.
95. Deleted at proof.
96. Glass R.M. Blue mood, blackened lungs - depression and smoking. JAMA. 264:1990;1583.
97. Picciotto M., Zoli M., Rimondini R., Léna C., Marubio L., Merlo Pich E.et al. β-2 subunit containing acetylcholine receptors are involved in the reinforcing properties of nicotine. Nature. 391:1998;173.
98. Picciotto M.R., Zoli M., Léna C., Bessis A., Lallemand Y., Le Novere N.et al. Abnormal avoidance learning in mice lacking functional high affinity nicotine receptor in the brain. Nature. 274:1995;65.
99. Pidoplichko V.I., DeBiassi M., Williams J.T., Dani J.A. Nicotine activates and desensitizes midbrain dopamine neurons. Nature. 390:1997;401.
100. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease. a disorder of cortical innervation Science. 219:1983;1184.
101. Araujo D.M., Lapchak P.A., Robitaille Y., Gauthier S., Quirion R. Differential alteration of various cholinergic markers in cortical and subcortical regions of the human brain in Alzheimer's disease. J Neurochem. 50:1989;1914.
102. Aubert I., Araujo D.M., Cecyne D., Robitaille Y., Gauthier S., Quirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's disease. J Neurochem. 58:1992;529.
103. Drachman D.A., Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol. 30:1976;113.
104. Sunderland T., Tarriot P.N., Weingartner H., Murphy D.L., Newhouse P.A., Mueller E.A.et al. Pharmacological modeling of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 10:1986;599.
105. Sugaya K., Giacobini E., Chiappinelli V.A. Nicotinic acetylcholine receptor subtypes in human frontal cortex. changes in Alzheimer's disease J Neurosci Res. 27:1990;349.
106. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G.et al. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease. possible index of early neuropathology Neuroscience. 64:1995;385.
107. Hecht K., Poppei M., Hecht T., Postnow J.W., Moritz V., Baumann R. Lern-und Gedachtnissprozesse wahrend der postnatalen ontogenese von Ratten mit spontaner hypertonie. Acta Biol Med. 37:1978;147.
108. Gattu M., Terry A.V., Pauly J.R., Buccafusco J.L. Cognitive impairment in spontaneously hypertensive rats. role of central nicotinic receptors Part II. Brain Res. 771:1997;104.
109. Zoli M, Picciotto M, Ferrari R, Changeux JP. A spatial learning deficit in aged mice lacking high-affinity nicotinic receptors. (Abstract). Soc Neurosci 1997;23.
110. Levin E.D. Nicotinic systems and cognitive function. Psychopharmacology. 108:1992;417.
111. Ksir C., Benson D.M. Enhanced behavioral response to nicotine in an animal model of Alzheimer's disease. Psychopharmacology (Berl). 81:1983;271.
112. Decker M.W., Majchrzak M.J., Anderson D.J. Effects of nicotine on spatial memory deficits in rats with septal lesions. Brain Res. 572:1992;281.
113. Hodges H., Allen Y., Sinden J., Mitchell S.N., Arendt T., Lantos P.L., Gray J.A. The effects of cholinergic drugs and cholinergic-rich foetal transplants on alcohol induced deficits in radial maze performance in rats. Behav Brain Res. 43:1991;7.
114. Buccafusco J.J., Jackson W.J. Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol Aging. 12:1991;233.
115. Brioni J.D., Arneric S.P. Nicotinic receptor agonists facilitate retention of avoidance training. participation of dopaminergic mechanisms Behav Neural Biol. 59:1993;57.
116. Jones G.M.M., Sahakian B.J., Levy R., Warburton D.M., Gray J.A. Effects of subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology. 108:1992;485.
117. Newhouse P., Sunderland T., Tariot P., Blumhardt C., Weingartner H., Mellow W. Intravenous nicotine in Alzheimer's disease. a pilot study Psychopharmacology. 95:1988;171.
118. Sahakian B., Jones G., Levy R., Gray J., Warburton D. The effects of nicotine on attention, information processing and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry. 154:1989;797.
119. Wesnes K., Warburton D.M. The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology. 82:1984;338.
120. Brazell M.P., Mitchell S.N., Joseph M.H., Gray J.A. Acute administration of nicotine increases the in vivo extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat. comparison with caudate-putamen Neuropharmacology. 29:1990;1117.
121. Brazell M.P., Mitchell S.N., Joseph M.H., Gray J.A. Effects of acute administration of nicotine on in vivo release of noradrenaline in the hippocampus of freely moving rats. a dose-response and antagonist study Neuropharmacology. 30:1991;823.
122. Wonnacott S., Irons J., Rapier C., Thorne B., Lunt G.G. Presynaptic modulation of transmitter release by nicotinic receptors. Prog Brain Res. 79:1989;157.
123. Nanri M., Kasahara N., Yamamoto J., Miyake H., Watanabe H. A comparative study on the effects of nicotine and GTS-21, a new nicotinic agonist, on the locomotor activity and brain monoamine level. Jpn J Pharmacol. 78:1998;385.
124. Tani Y., Saito K., Imoto M., Ohno T. Pharmacological characterization of nicotinic receptor-mediated acetylcholine release in rat brain - an in vivo microdialysis study. Eur J Pharmacol. 351:1998;181.
125. Meyer E.M., Kuryatov A., Gerzanich V., Lindstrom J., Papke R.L. Analysis of 3-α4-hydroxy, 2-methoxybenzylidene) anabaseine selectivity and activity at human and rat alpha-7 nicotinic receptors. J Pharmacol Exp Ther. 287:1998;918.
126. Wilkie G.I., Hutson P., Sullivan J.P., Wonnacott S. Pharmacological characterization of a nicotinic autoreceptor in rat hippocampal synaptosomes. Neurochem Res. 21:1996;1141.
127. Prendergast M.A., Jackson W.J., Terry A.V. Jr., Decker M.W., Arneric S.P., Buccafusco J.J. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology. 136:1998;50.
128. Prendergast M.A., Terry A.V. Jr., Jackson W.J., Marsh K.C., Decker M.W., Arneric S.P., Buccafusco J.J. Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418. Psychopharmacology. 130:1997;276.
129. Summers K.L., Lippiello P., Giacobini E. A microdialysis study of the effects of the nicotinic agonist RJR-2403 on cortical release of acetylcholine and biogenic amines. Neurochem Res. 21:1996;1181.
130. Lippiello P.M., Bencherif M., Gray J.A., Peters S., Grigoryan G., Hodges H., Collins A.C. RJR-2403. a nicotinic agonist with Cns selectivity. ii. In vivo characterization J Pharmacol Exp Ther. 279:1996;1422.
131. Calne D.B., Langston J.W. Aetiology of Parkinson's disease. Lancet. 2:1983;1457.
132. Moll H. The treatment of post-encephalitic parkinsonism by nicotine. BMJ. 1:1926;1079.
133. Fagerström K.O., Pomerleau O., Giordani B., Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology. 116:1994;117.
134. Lichtensteiger W., Hefti F., Felix D., Huwyler T., Melamed E., Schlumpf M. Stimulation of nigrostriatal dopamine neurons by nicotine. Neuropharmacology. 21:1982;963.
135. Kita T., Okamoto M., Nakashima T. Nicotine-induced sensitization of ambulatory stimulation effects produced by daily administration into the ventral tegmental area and nucleus accumbens in rats. Life Sci. 50:1992;583.
136. Baron J.A. Cigarette smoking and Parkinson's disease. Neurology. 36:1986;1490.
137. Schneider J.S., Tinker J.P., Van Velson M., Menzaghi F., Lloyd G.K. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. J Pharmacol Exp Ther. 290:1999;731.
138. Schneider J.S., Pope-Coleman A., Van Velson M., Menzaghi F., Lloyd G.K. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. Mov Disord. 13:1998;637.
139. Menzaghi F., Whelan K.T., Risbrough V.B., Rao T.S., Lloyd G.K. Interactions between a novel cholinergic ion channel agonist SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats. J Pharmacol Exp Ther. 280:1997;393.
140. Silver A.A., Hagin R.A. Gilles de la Tourette's Syndrome. Noshpitz J.D. Disorders of learning in childhood. Wiley Series in Adolescent Mental Health. 1990;John Wiley & Sons, New York. 469.p.
141. Riddle M.A., Hardin M.T., Ort S.I., Leckman J.F., Cohen D.J. Behavioral symptoms in Tourette's syndrome. Cohen D.J., Bruun R.D., Leckman J.F. Tourette's syndrome and tic disorders. clinical understanding and treatment. Wiley Series in Child and Adolescent Mental Health:1988;John Wiley & Sons, New York. 151.p.
142. Harris D., Silver A.A. Tourette's syndrome and learning disorders. Learning Disabil. 6:1995;1.
143. Singer H., Reiss J., Brown J. Volumetric MRI changes in basal ganglia of children with Tourette syndrome. Neurology. 43:1993;950.
144. Peterson B., Riddle M., Cohen D.J., Katz L.D., Smith J.C., Hardin M.T.et al. Reduced basal ganglia volumes in Tourette's syndrome using three-dimensional reconstruction techniques from magnetic resonance images. Neurology. 43:1993;941.
145. Hyde T.M., Stacey M.E., Coppola R. Cerebral morphometric abnormalities in Tourette's syndrome. a quantitative MRI study of monozygotic twins Neurology. 45:1995;1176.
146. Singer H.S., Butler I.J., Tune L.E., Seifert W.E., Coyle J.T. Dopaminergic dysfunction in Tourette syndrome. Ann Neurol. 12:1982;361.
147. Comings D.E., Comings B.G. A controlled study of the Tourette syndrome, I-VIII. Am J Hum Genet. 41:1987;701.
148. Swedo S.E. Sydenham's chorea. a model for childhood autoimmune neuropsychiatric disorders JAMA. 272:1994;1788.
149. Erenberg G., Cruse R.P., Rothner A.D. The natural history of the Tourette syndrome. a follow-up study Ann Neurol. 22:1987;383.
150. Shapiro A.K., Shapiro E.S. Treatmnet of tic disorders with haloperidol. Cohen D.J., Bruun R.D., Leckman J.F. Tourette's syndrome and tic disorders. clinical understanding and treatment. Wiley Series in Child and Adolescent Mental Health:1988;John Wiley & Sons, New York. 267.p.
151. Bruun R.D. Gilles de la Tourette's syndrome. an overview of clinical experience J Am Acad Child Adolesc Psychiatry. 23:1984;126.
152. Cohen D.J., Detlor J., Young J.G., Shaywitz B.A. Clonidine ameliorates Gilles de la Tourette's syndrome. Arch Gen Psychiatry. 37:1980;1350.
153. Riddle M.A., Hardin M.T., King R.A., Scahill L., Woolston J.L. Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders. preliminary clinical experience J Am Acad Child Adolesc Psychiatry. 29:1990;45.
154. Bruun R.D., Budman C.L. Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry. 57:1996;29.
155. Sanberg P.R., McConville B.J., Fogelson H.M., Manderscheid P.Z., Parker K.W., Blythe M.M., Klykylo W.M., Norman A.B. Nicotine potentiates the effects of haloperidol in animals and patients with Tourette syndrome. Biomed Pharmacother. 43:1989;19.
156. McConville B.J., Fogelson M.H., Norman A.B., Klykylo W.M., Manderscheid M.A., Parker K.W., Sanberg P.R. Nicotine potentiation of haloperidol is reducing tics frequency in Tourette's disorder. Am J Psychiatry. 148:1991;793.
157. McConville B.J., Sanberg P.R., Fogelson M.H., King J., Cirino P., Parker K.V., Norman A.V. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. Biol Psychiatry. 31:1992;832.
158. Silver A.A., Shytle R.D., Philipps M.K., Sanberg P.R. Transdermal nicotine in Tourette syndrome. Clarke P.B.S., Quik M., Thurau K. The effects of nicotine on biological systems. II. Advances in pharmacological sciences. 1995;Birkhauser Publishers, Boston. 293.p.
159. Dursan S.M., Reveley M.A., Bord R., Stirton F. Long lasting improvement of Tourette's syndrome with transdermal nicotine. Lancet. 344:1994;1577.
160. Shytle R.D., Silver A.A., Philipp M.K., McConville B.J., Sanberg P.R. Transdermal nicotine for Tourette's syndrome. Drug Dev Res. 38:1996;290.
161. Emerich D.F., Zanol M.D., Norman A.B., Sanberg P.R. Nicotine potentiates the behavioral effects of haloperidol. Psychopharmacol Bull. 27:1991;385.
162. Emerich D.F., Zanol M.D., Norman A.B., McConville B.J., Sanberg P.R. Nicotine potentiates haloperidol-induced catalepsy and hyperactivity. Pharmacol Biochem Behav. 38:1991;875.
163. Moss D.E., Manderscheid P.Z., Montgomery S.P., Norman A.B., Sanberg P.R. Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome. Life Sci. 44:1989;521.
164. 3H]dopamine release from mouse striatal synaptosomes. J Neurochem. 62:1994;1390.
165. Barkley R.A. Attention-deficit hyperactivity disorder. a handbook for diagnosis and treatment:1990;1 Guilford Press, New York.
166. Wender P.H., Wood D.R., Reimherr F.W. Pharmacological treatment of attention deficit disorder, residual type (ADD-RT) in adults. Greenhill L.L., Osman B.B. Ritalin. theory and patient management:1991;Mary Ann Liebert, New York. 25.p.
167. Saint-Cyr J.A., Taylor A.E., Nicholson K. Behavior and the basal ganglia. Adv Neurol. 65:1995;1.
168. Palumbo D., Maughan A., Kurlan R. Hypothesis III. Tourette syndrome is only one of several causes of a developmental basal ganglia syndrome. Arch Neurol. 54:1997;475.
169. Aylward E.H., Reiss A.L., Reader M.J., Singer H.S., Brown J.E., Denkla M.B. Basal ganglia volumes in children with attention-deficit hyperactivity disorder. J Child Neurol. 11:1996;112.
170. Castellanos F.X., Giedd J.N., Eckburg P. Quantitative morphology of the caudate nucleus in attention deficit hyperactivity disorder. Am J Psychiatry. 151:1994;1791.
171. Lou H.C., Henriksen L., Bruhn P., Borner H., Nielsen J.B. Striatal dysfunction in attention deficit and hypekinetic disorder. Arch Neurol. 46:1989;48.
172. Pomerleau O.F., Downey K.K., Stelson F.W., Pomerleau C.S. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse. 7:1995;373.
173. Peeke S.C., Peeke H.V. Attention, memory and cigarette smoking. Psychopharmacology. 84:1984;205.
174. Warburton D.M., Rusted J.M., Fowler J.A. Comparison of the attentional and consolidation hypotheses for the facilitation of memory by nicotine. Psychopharmacology. 108:1992;443.
175. US Surgeon General's report on the health consequences of smoking, nicotine addiction (Washington DC, U.S. Government Printing Office); DHHS (CDC) 88-8406 1988. p. 618.
176. Levin E.D., Conners C.K., Sparrow E., Hinton S.C., Erhardt D., Meck W.H., Rose J.E., March J. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology. 123:1996;55.
177. Wonnacott S., Irons J., Rapier C., Thorne B., Lunt G.G. Presynaptic modulation of transmitter release by nicotinic receptors. Prog Brain Res. 79:1989;157.
178. Clarke P.B.S., Pert A. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res. 348:1985;355.
179. Clarke P.B.S., Pert C.B., Pert A. Autoradiographic distribution of nicotinic receptors in rat brain. Brain Res. 323:1984;390.
180. 3H]acetylcholine in rat brain. Life Sci. 38:1986;2111.
181. Clarke P.B.S., Hommer D.W., Pert A., Skirboll L.R. Electrophysiological actions of nicotine on substantia nigra single units. Br J Pharmacol. 85:1985;827.
182. Grenhoff J., Aston-Jones G., Svensson T.H. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand. 128:1986;151.
183. Imperato A., Mulas A., Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol. 132:1986;337.
184. Goff D.C., Henderson D.C., Amico C. Cigarette smoking in schizophrenia. relationship to psychopathology and medication side effects Am J Psychiatry. 2149:1992;1189.
185. Hughes J.R., Hatsukami D.K., Mitchell J.E., Dahlgren L.A. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry. 143:1986;993.
186. Masterson E., O'Shea B. Smoking and malignancy in schizophrenia. Br J Psychiatry. 145:1984;429.
187. Greeman M., McClellan T.A. Negative effects of a smoking ban in patient psychiatry service. Hosp Community Psychiatry. 42:1991;408.
188. Burton-Bradley B.G. Arecaidine and schizophrenia. Letter. Am J Psychiatry. 135:1978;506.
189. Adler L.E., Hoffer D.L., Wiser B.A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 150:1993;1856.
190. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davisa A.et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA. 94:1997;587.
191. Freedman R., Hall M., Adler L.E., Leonard S. Evidence in postmortem brain tissue for decreased number of hippocampal nicotinic acetylcholine receptors in schizophrenia. Biol Psychiatry. 38:1995;22.
192. Griffith J.M., O'Neill E.J., Petty F., Garver D., Young D., Freedman R. Nicotinic receptor desenzitization and sensory gating deficits in schizophrenia. Biol Psychiatry. 44:1998;98.
193. Klein C., Andersen B. On the influence of smoking upon smooth pursuit eye movement of schizophrenic and normal controls. J Psychophysiology. 5:1991;361.
194. Denny-Brown D., Fisher E.G. Physiological aspects of visual perception. II. the subcortical visual direction of behavior Arch Neurol. 33:1976;228.
195. Tsumoto T., Suzuki D.A. Effects of frontal eye field stimulation upon activities of lateral geniculate body in the cat. Exp Brain Res. 25:1976;291.
196. 3H]nicotine Acta Physiol Scand. 132:1988;1.
197. Wilner P. Dopamine and depression. a review of recent evidence. III. The effects of antidepressant treatments Brain Res Rev. 6:1983;237.
198. Swerdlow N.R., Koob J.F. Dopamine, schizophrenia, mania and depression. toward a unified hypothesis of cortico-striato-pallido-thalamic function Behav Brain Sci. 10:1987;197.
199. Ferguson D.M., Lynskey M.T., Horwood L.J. Comorbidity between depressive disorders and nicotine dependence in a cohort of 16-year-olds. Arch Gen Psychiatry. 53:1996;1043.
200. Breslau N., Kilbey M.M., Andreski P. Nicotine withdrawal symptoms and psychiatric disorders. findings from an epidemiological study of young adults Am J Psychiatry. 149:1992;464.
201. Covey L.S., Glassman A.H., Stetner F. Depression and depressive symptoms in smoking cessation. Compr Psychiatry. 31:1990;350.
202. Covey L.S., Glassman A.H., Stetner F. Major depression following smoking cessation. Am J Psychiatry. 154:1997;263.
203. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., MacGregor R. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 379:1996;733.
204. Berlin I., Saïd S., Spreux-Varoquaux O., Launay J.M., Olivares R., Millet V., Lecrubier Y., Puech A.J. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther. 58:1995;444.
205. Salín-Pascual R.J., Drucker-Colín R. A novel effect of nicotine on mood and sleep in major depression. Neuroreport. 9:1998;57.
206. Vázquez J., Guzmán-Marín R., Salín-Pascual R., Drucker-Colín R. Transdermal nicotine on sleep and PGO spikes. Brain Res. 737:1996;317.
207. Blier P., de Montigny C., Chaput Y. Modifications of the serotonin system by antidepressant treatments. implications for the therapeutic response in major depression J Clin Psychopharmacol. 7:1987;24S.
208. Jacobs B.L., Asher R., Dement W.C. Electrophysiological and behavioral effects of electrical stimulation of the raphe nuclei in the cat. Phys Behav. 11:1973;489.
209. Mihailescu S., Palomero-Rivero M., Meade-Huerta P., Maza-Flores A., Drucker-Colín R. Effects of nicotine and mecamylamine on rat dorsal raphe neurons. Eur J Pharmacol. 360:1998;31.
210. Scheffer I.E., Bhatia K.P., Lopes-Cendes I., Fish D.R., Marsden C.D., Andermann E., Desbiens R., Cendes F., Manson J.I. Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder. Lancet. 343:1994;515.
211. Philips H.A., Scheffer I.E., Berkovic S.F., Holway G.E., Sutherland G.R., Mulley J.C. Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q 13.2. Nature Genet. 10:1995;117.
212. Steinlein O., Mulley J., Propping P., Wallace R., Philipps H., Sutherland G., Scheffer I.E., Berkovic S.F. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet. 11:1995;201.
213. Akabas M., Kaufmann C., Archdeacon P., Karlin A. Identification of acetylcholine receptor channel-lining residues in the entire M2 segment of the α subunit. Neuron. 13:1994;919.
214. Steinlein O., Magnusson A., Stoodt J., Bertrand S., Weiland S., Berkovic S.F., Nakken K.O., Propping P., Bertrand D. An insertion mutation of the CHRNA4 gene in a family with autosomal dominant nocturnal lobe epilepsy. Hum Mol Genet. 6:1997;943.
215. Bertrand S., Weiland S., Berkovic S.F., Steinlein O.K., Bertrand D. Properties of neural acetylcholine receptors mutants from humans suffering from autosomal dominant nocturanal frontal lobe epilepsy. Br J Pharmacol. 125:1998;751.
216. 2+ permeability, conductance, and gating of human alpha4beta2 nicotinic acetylcholine receptors. J Neurosci. 17:1997;9035.
217. Daubas P., Devillers-Thiéry A., Geoffroy B., Martinez S., Bessis A., Changeux J.P. Differential expression of the neuronal acetylcholine receptor 2 subunit gene during chick brain development as detected by in situ hybridization and cDNA amplification. Neuron. 5:1990;49.
218. Wada E., Wada K., Boulter J., Deneris E., Heinemann S., Patrick J., Swanson L.W. Distribution of alpha2, alpha3, alpha 4 and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system. a hybridization histochemical study in the rat J Comp Neurol. 284:1989;314.
219. Dineley-Miller K., Patrick J. Gene transcripts for the nicotinic acetylcholine receptor are subunit β4 are distributed in multiple areas of the rat central nervous system. Mol Brain Res. 16:1992;339.
220. Deneris E.S., Boulter J., Swanson L.W., Patrick J., Heinemann S. Beta 3. a new member of acetylcholine receptor gene family is expressed in brain J Biol Chem. 264:1989;6268.
221. Wada E., McKinnon D., Heinemann S., Patrick J., Swanson L.W. The distribution of mRNA encoded by a new member of the neuronal nicotinic acetylcholine receptor gene family (alpha 5) in the rat central nervous system. Brain Res. 27:1990;526.
222. Hill J.A., Zoli M., Bourgeois J.P., Changeux J.P. Immunocytochemical localization of of a neuronal nicotinic receptor. the beta2 subunit J Neurosci. 13:1993;1551.